Answers are grounded in this paper and cite their sources.
For Pola-BR, the objective response rate (ORR) was 62.5% (complete response [CR] rate was 50%). Median progression-free survival (PFS) a at 9.2 months and overall survival (OS) at 12.4 months were both superior for Pola-BR. 9 A single-arm expansion cohort identified primary refractory
No takes yet. Share an insight, caveat, or question.
Northend et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: